NEW YORK (GenomeWeb News) – Poland's University of Lodz will use Cellectricon's cell-based screening system in its genomic research programs, the company said today.

Under the agreement, the university will use the Cellaxess HT system for high-throughput transfection, which the company said enables the delivery of any genetic material to cells without the use of reagents.

The university bought the Cellaxess system with funding from Poland's Innovative Economy Operational Program, which is supported in part by the EU's European Regional Development Fund.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.